Variability of the Glycoprotein G Gene in Clinical Isolates of Herpes Simplex Virus Type 1

ELHAM REKABDAR,1 PETRA TUNBÄCK,1,2 JAN-ÅKE LILJEQVIST,1 AND TOMAS BERGSTROM1*

Departments of Clinical Virology1 and Dermatology,2 Göteborg University, Göteborg, Sweden

Received 3 May 1999/Returned for modification 14 July 1999/Accepted 31 August 1999

Glycoprotein G (gG) of herpes simplex virus type 1 (HSV-1) has been used as a prototype antigen for HSV-1 type-specific serodiagnosis, but data on the sequence variability of the gene coding for this protein in wild-type strains are lacking. In this study, direct DNA sequencing of the gG-1 genes from PCR products was performed with clinical HSV-1 isolates from 11 subjects as well as with strains Syn 17*, F, and KOS 321. The reference strains Syn 17* and F showed a high degree of conservation, while KOS 321 carried 13 missense mutations and, in addition, 12 silent mutations. Three clinical isolates showed mutations leading to amino acid alterations: one had a mutation of K32 to N, which is a gG-1-to-gG-2 alteration; another contained all mutations which were observed in KOS 321 except two silent mutations; and the third isolate carried five missense mutations. Two clinical isolates as well as strain KOS 321 showed a mutation (F111→V) within the epitope of a gG-1-reactive monoclonal antibody (MAb). When all viruses were tested for reactivity with the anti-gG-1 MAb, the three strains with the F111→V mutation were found to be unreactive. Furthermore, gG-1 antibodies purified from sera from the two patients carrying strains mutated in this epitope were less reactive when they were tested by an HSV-1-infected-cell assay. Therefore, our finding that the sequence variability of the gG-1 gene also affects B-cell epitope regions of this protein in clinical isolates may have consequences for the use of this protein as a type-specific antigen for serodiagnosis.

The two subtypes of herpes simplex virus (HSV), HSV-1 and HSV-2, are genetically highly homologous, but despite this their respective tropisms and clinical pictures of infection differ (23). Type-discriminating diagnostic methods include (i) virus isolation followed by serological typing and (ii) DNA detection, both of which are applicable during active infection, and (iii) serodiagnosis, which is applicable during latent or low-replication phases of infection (1).

A reliable type-specific diagnosis may be of importance for several reasons: (i) for optimal dosage of antiviral treatment since sensitivities to antivirals differ between the two viral subtypes (10), (ii) for counseling of couples where one of the partners has genital herpes, (iii) to provide means for HSV seroepidemiological studies to be based on seroassays of high specificity and sensitivity (13), and (iv) to evaluate efficacy during trials of HSV prophylactic agents, including vaccines, by determining frequencies of type-specific seroconversions.

The development of HSV type-specific diagnostic methods for viral typing and serodiagnosis has been hampered by the reported extensive intertypic cross-reactivity between several of the HSV envelope glycoproteins (1, 5). For viral typing with polyclonal sera, the existence of single cross-reactive epitopes in HSV glycoproteins may disqualify their use as type-specific targets, especially since such epitopes may be present in most HSV strains (9, 32) and may lead to serological cross-reactivity (7).

Glycoprotein G (gG) is the candidate antigen for serological analysis of the type-specific antibody response in individuals infected with HSV-1 and/or HSV-2 (2, 15, 28). Although data on epitope mapping are incomplete, no cross-reactive anti-gG-1 (18) or gG-2 monoclonal antibodies (MAbs) have hitherto been reported (20). Therefore, of all the HSV-1 envelope proteins, gG-1 appears to be the best choice for an HSV-1-specific antigen for clinical serodiagnosis and possibly also for routine typing of viral isolates. Recently, an evaluation of a commercial gG-based enzyme immunoassay (EIA) supported this assumption (3). When basing type-specific diagnosis on a single antigen such as gG-1, a prerequisite is that the gene coding for this protein is conserved in clinical isolates. The aim of this study was to sequence the HSV-1 gG gene in clinical isolates derived from different localities by a PCR-based system, in order to determine the genetic variability of this gene. In addition, we investigated the clinical isolates for exposure of the gG-1 antigen on infected cells by the use of a gG-1-reactive MAb and purified polyclonal human anti-gG-1 antibodies. Here, we detected a genetic gG-1 variant of HSV-1 totally lacking a type-specific epitope.

MATERIALS AND METHODS

Patients and viral strains. Ten patients (designated patients 1 to 10) with reactivated herpetic cutaneous lesions from different localities of the body (mouth, neck, finger, and genitals), seen at outpatient departments in Göteborg, Sweden, were randomly chosen for investigation. Green monkey kidney (GMK) cells were used for isolation, and all strains were then stored frozen at −70°C. From each patient, one HSV-1 isolate and a simultaneously drawn serum sample were included. In addition, a cerebrospinal fluid (CSF) strain (designated HSV-1 BAN) isolated from a patient during her first attack of multiple sclerosis was included (6). HSV strains were isolated and typed by the use of the type-specific MAbs (24). The HSV-1 reference strains used were Syn 17*, F, and KOS 321 (a plaque-purified isolate of wild-type KOS 321), and the HSV-2 strain used was 333.

All patients were previously found to be seropositive for a type-common HSV antigen, as well as for an HSV-1 type-specific gG-1 antigen (31). Four of the patients were also seropositive for HSV-2 by Western blotting (Table 1). These serum samples were used for the purification of gG-1 antibodies in this study.

MAbs. The following HSV-1 type-specific MAbs were used: a commercially available anti-gG-1 MAb (Advanced Biotechnologies, Cambridge, United Kingdom), which was previously mapped to amino acids A, F, P, and L at positions 110 to 113 (31), and the anti-gG-1 MAb 1B1C1B4, which is reactive with a type-specific epitope shown to be conserved in clinical isolates (21). The anti-gB-1 MAb 1B11D8, reactive with a type-common epitope (8), was used as a
were performed by using a QIAamp Blood kit (Qiagen, Gothenburg, Sweden). DNA extraction of HSV-1 isolates was used at a concentration of 10 pmol/l. DNA extraction of HSV-1 isolates was previously exploited for diagnosis of HSV-1-induced central nervous system infections (4, 27). For DNA sequencing, we first developed and optimized a PCR system amplifying the type-specific promoter region of the gD-1 or gD-2 gene, which was selected due to the high G+C content of the sequence. All PCRs were carried out with a Perkin-Elmer (Gothenburg, Sweden) DNA thermal cycler. The two-step amplification consisting of 1 min of denaturation program started with an initial denaturation of 2 min 30 s at 94°C, 1 min at 50°C, and 4 min at 60°C. The sequencing reaction was carried out in both the sense and antisense directions for confirmation and also as an internal control. After cyclic sequencing, the products were precipitated with ethanol, dissolved in template suppression reagent, and then denatured. The sequencing was carried out on an automated sequencer (ABI Prism, 310 Genetic analyzer; Perkin-Elmer). All HSV-1 strains carrying alterations of the DNA sequence were resequenced one to three times for confirmation.

**TABLE 1. Clinical characteristics and IgG titers of 11 patients with recurrent HSV-1 infection and results of a nested-PCR system used for typing of the viral isolates**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Site of lesions</th>
<th>Type-common antigen</th>
<th>gG-1 antigen</th>
<th>HSV-1</th>
<th>HSV-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>35</td>
<td>Lip</td>
<td>3,200 ± 4,600</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>67</td>
<td>Vulva</td>
<td>6,400 ± 800</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>37</td>
<td>Lip</td>
<td>12,800 ± 3,200</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>32</td>
<td>Lip</td>
<td>3,200 ± 1,600</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>64</td>
<td>Lip</td>
<td>± 4,600 ± 3,200</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>76</td>
<td>Lip</td>
<td>± 6,400 ± 600</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>36</td>
<td>Neck</td>
<td>200 ± 800</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>61</td>
<td>Finger</td>
<td>200 ± 400</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>56</td>
<td>Lip</td>
<td>± 4,600 ± 3,200</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>28</td>
<td>Lip</td>
<td>1,600 ± 1,600</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>52</td>
<td>Brain</td>
<td>± 3,200 ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*Serological data are from the work of Tunback et al. (31). ND, not determined.

**TABLE 2. Primers used for PCR DNA sequencing**

<table>
<thead>
<tr>
<th>Primer</th>
<th>Nucleotide positions</th>
<th>Primer length (bp)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>4046–4068</td>
<td>23</td>
<td>5’TGTTCACCGAGATGACGCCGCC3’</td>
</tr>
<tr>
<td>B</td>
<td>4421–4402</td>
<td>20</td>
<td>5’TCTAAGTAGTGCCTGCCTC3’</td>
</tr>
<tr>
<td>C</td>
<td>4335–4352</td>
<td>18</td>
<td>5’ACGCCCGACCACACACC3’</td>
</tr>
<tr>
<td>D</td>
<td>4667–4648</td>
<td>20</td>
<td>5’TATGTTAGGCGTCGGACGACC3’</td>
</tr>
<tr>
<td>E</td>
<td>4563–4580</td>
<td>18</td>
<td>5’AGTCGCCGCGACCGACACC3’</td>
</tr>
<tr>
<td>F</td>
<td>4892–4875</td>
<td>18</td>
<td>5’CCGATGCTGGGCTCCTCC3’</td>
</tr>
</tbody>
</table>

*According to the gG-1 DNA sequence reported by McGeoch et al. (22).

**TABLE 3. Results of DNA sequencing of the gG-1 gene indicating sites of mutations in 11 clinical HSV-1 isolates and two laboratory strains, compared with Syn 17**

<table>
<thead>
<tr>
<th>Codon position(s)</th>
<th>Codon</th>
<th>Mutationa</th>
<th>Amino acid substitution</th>
<th>Mutated HSV-1 strain(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>ATG</td>
<td>ACC</td>
<td>None</td>
<td>KOS 321, F, 1–9, 11</td>
</tr>
<tr>
<td>3</td>
<td>CAG</td>
<td>CCG</td>
<td>Q→P</td>
<td>KOS 321, F, 1–9, 11</td>
</tr>
<tr>
<td>20</td>
<td>GTT</td>
<td>G</td>
<td>None</td>
<td>9</td>
</tr>
<tr>
<td>66</td>
<td>ACG</td>
<td>ACA</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td>76</td>
<td>ATT</td>
<td>TCC</td>
<td>None</td>
<td>KOS 321, F, 1–11</td>
</tr>
<tr>
<td>82</td>
<td>CCC</td>
<td>C</td>
<td>E</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>89</td>
<td>GAT</td>
<td>G</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>94</td>
<td>GAG</td>
<td>AAG</td>
<td>E→K</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>108</td>
<td>GCC</td>
<td>GT</td>
<td>None</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>111</td>
<td>TTC</td>
<td>GTC</td>
<td>F→V</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>114</td>
<td>GCC</td>
<td>G</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>115</td>
<td>GAG</td>
<td>GGG</td>
<td>E→G</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>116</td>
<td>GAC</td>
<td>GAT</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>119</td>
<td>GTC</td>
<td>GAC</td>
<td>V→D</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>119</td>
<td>AAG</td>
<td>AAA</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>121</td>
<td>AAA</td>
<td>AAC</td>
<td>K→N</td>
<td>6</td>
</tr>
<tr>
<td>129</td>
<td>TCC</td>
<td>CCC</td>
<td>S→P</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>131</td>
<td>GAT</td>
<td>GGT</td>
<td>D→G</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>143</td>
<td>CGC</td>
<td>CAG</td>
<td>None</td>
<td>KOS 321, 7, 9</td>
</tr>
<tr>
<td>150</td>
<td>ATT</td>
<td>AGT</td>
<td>I→S</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>157</td>
<td>CGC</td>
<td>CCA</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>161</td>
<td>CCA</td>
<td>CAA</td>
<td>R→Q</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>163</td>
<td>ACC</td>
<td>CCC</td>
<td>T→P</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>166</td>
<td>GGA</td>
<td>GGG</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>204</td>
<td>TTG</td>
<td>GTG</td>
<td>L→V</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>207</td>
<td>GGT</td>
<td>GTT</td>
<td>G→V</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>208</td>
<td>GCG</td>
<td>GCT</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>215</td>
<td>GGC</td>
<td>GGT</td>
<td>None</td>
<td>KOS 321, 7</td>
</tr>
<tr>
<td>235</td>
<td>TCC</td>
<td>CCC</td>
<td>S→P</td>
<td>KOS 321, 7</td>
</tr>
</tbody>
</table>

*Boldface type indicates the mutation.

*a A triple-C insert was detected at this position in two strains."
RESULTS

Typing of HSV isolates. All clinical isolates were positive for the HSV-1 type-specific MAb B1C1 reactive with gC (8, 24) but were negative for the HSV-2 anti-gG-2 MAb O1C5 and were therefore classified as HSV-1 (data not shown). Further-
more, typing by a PCR method exploiting the type-specific differences in the promoter region of the gD gene (27) showed that all isolates were positive for HSV-1-specific, but not HSV-
2-specific, DNA amplification targeting this region (Table 1).

Sequence alterations in the gG-1 gene. We found a DNA sequence of strain Syn 17\textsuperscript{1} identical with a sequence previously published (22). The results from the sequencing of the 11 clinical HSV-1 isolates and strains Syn 17\textsuperscript{1}, KOS 321, and F are shown in Table 3, and the deduced amino acid sequence alterations are depicted in Fig. 1. The DNA sequences of the gG-1 gene from the following eight strains were almost identical: F and clinical isolates 1 to 5, 8, and 11 (HSV-1 BAN) (Table 3). They all differed from the reference strain Syn 17\textsuperscript{1} at one amino acid position, i.e., position 3, where they had a P rather than a Q, and in addition, strains 6, 7, 9, and KOS 321 also carried this substitution (Table 3 and Fig. 1). Furthermore, these 12 strains all carried two additional nucleotide alterations: the triplet ATT at the postulated noncoding region at codon position -9 was changed to ACC, and the codon ATT (Ile\textsubscript{76}) was replaced by ATC (Table 3). Clinical isolate 10 shared only the alteration of ATT (Ile\textsubscript{76}) to ATC but was otherwise completely identical with the DNA sequence of Syn 17\textsuperscript{1} (Table 3). The triplet CCG coding for proline at codon position 3 as well as the lack of an additional possible methi-
onine codon at -9 might be considered a consensus sequence in the investigated strains. Resequencing of strains KOS 321, 6, 7, and 9 gave results identical to those from the first round of sequencing of those strains.

Three clinical isolates showed additional sequence alter-
ations (Tables 3 and Fig. 1). Clinical isolate 6 had a single amino acid mutation of K\textsubscript{121} to N, which is a gG-1-to-gG-2 substitution, but adhered completely to the consensus se-
quence with this exception. Two isolates carried extensive mu-

![Fig. 1. Variability in the gG-1 genes of clinical isolates (Clin. isol.) and reference strains, with the variability being reflected in the deduced amino acid sequences. The proposed immunodominant region of gG-1 is shaded, and the sequence of the epitope of an anti-gG-1 MAb is depicted in boldface type and underlined.](http://cvi.asm.org/...)}
the other eight clinical isolates as well as to the reference strain (31). In contrast, the gG-1 MAb showed high reactivity to all of these isolates within the previously mapped AFPL epitope of the MAb (31). To further investigate gross strain differences in the expression of epitopes and comparable absorbance values to those of all strains tested. The DNA sequence of the gG-1 gene in the HSV-1 isolates from patients 1 and 2 were identical to the consensus sequence, while isolates 7 and 9 carried several mutations within the immunodominant epitope region (see above). The purified antibodies were sensitive to freezing and thawing since the sample from patient 5 gave a somewhat lower reactivity in two repetitions (data from one of these experiments is shown in Table 5) than it did in the previous experiments (Table 4). The results with purified antibodies from patients 7 and 9 showed low reactivities to all tested strains which could not be discriminated from the background of seroreactivity to uninfected cells (absorbance, 0.17 ± 0.04 versus 0.1 ± 0 [means ± standard deviations]). However, purified antibodies from both patients 1 and 5 gave clear reactivities to most strains (absorbance, 0.39 ± 0.13), with the exception of serum from patient 1, which did not react to strain KOS and strain 7.

### DISCUSSION

A prerequisite for using gG-1 as a type-specific antigen for serology is the genetic stability of the gene coding for this protein, or at least of its immunogenic regions, in clinical isolates. We found that KOS 321, a strain widely used in different laboratories, surprisingly contained 25 mutations, of which 13 were missense and 1 was a triplet insertion. In addition to the presence of a type-specific epitope on gG-1, evaluated by reactivity with a gG-1-specific MAb by ELISA of infected GMK cells, the two clinical isolates 7 and 9, as well as the reference strain KOS 321, showed no reactivity at all (Table 4) in parallel with the HSV-2 reference strain 333. As a likely explanation, all three HSV-1 strains contained the F111-V mutation situated within the previously mapped AFPL epitope of the MAb (31). In contrast, the gG-1 MAb showed high reactivity to all of the other eight clinical isolates as well as to the reference strain F (Table 4).

### Reactivities to human polyclonal anti-gG-1 antibodies.

To investigate gross strain differences in the expression of epitopes reactive with human antibodies, purified anti-gG-1 antibodies from one patient (patient 5) were assayed for reactivities to all hereinafter studied HSV-1 strains. This patient carried an HSV-1 strain displaying a normal gG-1 sequence, and her unpurified serum sample showed strong reactivity in a gG-1 ELISA (Table 1). Due to the small amount of gG-1 antibodies present in human sera and possible losses during extraction (31), the purified antibodies from patient 5 in general showed relatively low reactivities. In addition, the infected-cell assay depends on the expression of gG-1 by different HSV-1 strains, and in all cases, a relatively low expression of this protein was noted in comparison with that of gC-1, as could be deduced from the respective MAb signals (Table 4). However, all HSV-1 strains, including KOS and clinical isolates 7 and 9, showed clear reactivities with the purified human anti-gG-1 antibodies (Table 4). In contrast, strain 333 showed no reactivity, confirming a type-specific behavior of purified human gG-1 antibodies, even when they are purified from a patient showing antibodies also to gG-2 (Table 4).

### TABLE 4. Absorbance values from an ELISA after binding of HSV type-specific MAbs and purified human anti-gG-1 antibodies to GMK cells infected with different HSV strains

<table>
<thead>
<tr>
<th>HSV-1 strain or clinical isolate</th>
<th>Mean absorbance ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anti-gG-1 MAb</td>
</tr>
<tr>
<td>1</td>
<td>1.30 ± 0.16</td>
</tr>
<tr>
<td>2</td>
<td>0.90 ± 0.07</td>
</tr>
<tr>
<td>3</td>
<td>1.20 ± 0.05</td>
</tr>
<tr>
<td>4</td>
<td>1.60 ± 0.10</td>
</tr>
<tr>
<td>5</td>
<td>1.20 ± 0.01</td>
</tr>
<tr>
<td>6</td>
<td>1.00 ± 0.01</td>
</tr>
<tr>
<td>7</td>
<td>0.14 ± 0.01</td>
</tr>
<tr>
<td>8</td>
<td>1.60 ± 0.09</td>
</tr>
<tr>
<td>9</td>
<td>0.13 ± 0.01</td>
</tr>
<tr>
<td>10</td>
<td>1.40 ± 0.02</td>
</tr>
<tr>
<td>F</td>
<td>1.30 ± 0.02</td>
</tr>
<tr>
<td>KOS 321</td>
<td>0.15 ± 0.01</td>
</tr>
<tr>
<td>HSV-2 (333)</td>
<td>0.20 ± 0.01</td>
</tr>
<tr>
<td>Uninfected cells</td>
<td>0.10 ± 0.01</td>
</tr>
</tbody>
</table>

* Serum from patient 5.
tion, 2 of 11 investigated clinical isolates contained mutations resembling those found in KOS 321. One clinical isolate (isolate 7) showed all of the 13 missense mutations and the triplet insertion found in KOS 321 but lacked two silent mutations of the latter. Another clinical isolate (isolate 9) contained 6 of the 13 KOS 321 missense mutations. Since the rest of the analyzed sequences were almost completely conserved, the mutations represented by strains KOS 321, 7, and 9 may suggest a restricted genetic variability of the gG-1 gene outside the genotypic variability represented by KOS 321.

In a previous study, strains isolated from oral lesions exhibited a low genetic variability while the subclinical isolates derived from immunosuppressed patients diverged substantially (29). Although sequence information regarding the gG-1 gene in clinical isolates is currently lacking, data on the genetic variability of other HSV glycoproteins are accumulating. When the gB, gC, and gD genes were sequenced from five isolates of HSV-2, they were generally found to be conserved but different allelic forms were detected (30). Likewise, PCR-generated gB sequences amplified directly from the CSF of patients with encephalitis showed different alleles, especially in the aminoterminal part of the protein (26). In comparison to the minor sequence alterations reported in these studies, the herein described missense mutations of the gG-1 genes in strains KOS 321, 7, and 9 seem to be an uncommon finding.

In neither of the above-mentioned studies could the HSV variants be associated with a particular site of the body or with virulence properties. Likewise, of the gG-1 variants found in our study, one was isolated from the neck of a patient but the other was an ordinary oral isolate. In contrast, our HSV-1 strains derived from the genital tract as well as from CSF showed consensus sequences in their gG-1 genes. Hence, it seems unlikely that the gG-1 variants described here are related to properties of tropism or virulence. In another study describing allelic variants of gB in human herpesvirus 7, the differences were suggested to be related to the geographical origin of the host (12).

One of the missense mutations (F111→V) which were detected in KOS 321 and the two clinical isolates with KOS-like gG-1 sequences was localized within the epitope of a previously mapped anti-gG-1 Mab (31). Accordingly, these three strains showed absorbance values similar to the background value when reactivity was determined by ELISA of cells infected with the respective strains. These results confirmed the previous epitope mapping of the gG-1 Mab to 110AFPL114, of which F111 in mutational analysis of the reactive peptides was found to be of key importance for binding of the Mab, since substitution of any other amino acid for phenylalanine abolished reactivity (19). In addition, this finding indicates that this gG-1 Mab, although reactive with an HSV-1-specific domain of the type-specific gG-1 protein, would not be suitable for typing of HSV-1 isolates due to the genetic variability of the epitope region. However, although the mutated strains showed a slightly lower reactivity to a purified human anti-gG-1 serum, all three viruses were clearly reactive with the polyclonal antibodies derived from the patient harboring a strain with no alteration in the gG-1 sequence.

These findings of the genetic variability of the gG-1 gene raise the question of whether the antibody response to gG-1 is altered in these patients, which might lead to false-negative results in serological assays in which the gG-1 protein is the only antigen. The selected study population with symptomatic, recurrent herpes simplex infections generally showed strong antibody responses both to the type-common membrane antigen and to recombinant gG-1 by ELISA. Also, sera from the two patients (7 and 9) harboring the gG-1 mutation strains displayed a clear reactivity in this assay and would hence not become false-negative in HSV-1 serotesting. In the patients tested in this study, reactivities to remaining epitopes were evidently sufficiently strong to produce a positive reaction in an assay testing reactivity of whole sera with relatively large amounts of gG-1.

However, when gG-1 antibodies, purified against the consensus sequence gG-1 antigen, from patients 7 and 9, who carry gG-1 mutation strains, were tested on cells infected with a variety of strains, the reactivities did not differ from the background. This finding indicates a difference in the levels of antigen presentation of the two gG-1 variants, leading to lower yields of purified gG-1-reactive antibodies from the sera of patients carrying KOS-like variants. This antigenic difference between the gG-1 variants might have consequences for serotesting. Although an initial report indicated a sensitivity of 94% for patients with recurrent oral herpes (18) by a highly efficient gG-1 immunodot assay, a recent study has indicated a lower sensitivity (89%) when gG-1 was used as the EIA antigen for testing of sera collected from isolation-proven patients (14). In the latter study, the performance of the gG-1 EIA was clearly worse than that of the gG-2 EIA for HSV-2-specific serology. Another problem recently reported with the gG-1 ELISA is an inconsistency of results from serial samples from the same patient (25). The eventual role of viral genetic variability in these limitations in the use of gG-1 as a seroantigen may be considered.

We suggest that, in addition to influence from a possibly lower IgG response due to low expression of gG-1 during natural infection, the lower sensitivity of gG-1-based seroassays might be influenced by the variability of the gene coding for this protein among clinical isolates. It should be of interest to perform further sequencing of the gG-1 gene in asymptomatically shedded viruses isolated from immunosuppressed patients and to define the seroresponses to this protein in this category of hosts as part of attempts to improve HSV-1-specific serology.

ACKNOWLEDGMENTS

We thank Maria Johansson for technical advice. Financial support was received from the Swedish Medical Research Council (grant 11225), the LUA Foundation at the Sahlgren’s University hospital, the Göteborg, Medical Society of Göteborg, Sweden, and the Swedish Society for Medical Research.

REFERENCES


19. Liljeqvist, J. Ä. Personal communication.


